CME: New Directions on Therapeutic Drug Monitoring in IBD

New Directions on Therapeutic Drug Monitoring in IBD

New Directions on Therapeutic Drug Monitoring in IBD
RestartResume
Learn more about TNF inhibitors and therapeutic drugs for the treatment of IBD through patient cases and data from recent studies.

Available credits: 0.75

Time to complete: 45 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    This innovative, case-based CME activity features two prominent faculty covering important, timely issues and data related to the treatment and monitoring of inflammatory bowel disease (IBD). Using case studies, the faculty will explore diagnosis and management strategies to maximize patient care. Topics will include:

    • Challenges with TNF Inhibitor Treatment for IBD
    • Why Reactive and Proactive Therapeutic Drug Monitoring Optimizes Treatment
    • Case Studies on Algorithmic Therapeutic Drug Monitoring 
  • Provider(s)/Educational Partner(s)

    Jointly provided by Postgraduate Institute for Medicine (www.pimed.com) and Medtelligence.

       

  • Commercial Support

    This activity is supported by an independent educational grant from Quest Diagnostics.

  • Target Audience

    This activity is intended for Gastroenterology, Internal Medicine, Family Practice, and General Practice physicians who are engaged in the care of patients with inflammatory bowel disease.

  • Learning Objectives

    After completing this activity, the participant should be better able to:

    • Describe the challenges of treatment of irritable bowel disease (IBD) with TNF inhibitors
    • Relate the importance of proactive and reactive therapeutic drug monitoring when using TNF inhibitors for IBD management
    • Apply algorithms to the use of therapeutic drug monitoring to optimize TNF inhibitor therapy in patients with IBD
  • Faculty

    Adam S. Cheifetz, MD
    Associate Professor of Medicine
    Harvard Medical School
    Director, Center for Inflammatory Bowel Disease
    Beth Israel Deaconess Medical Center
    Boston, MA

    Alan C. Moss, MD
    Associate Professor of Medicine
    Harvard Medical School
    Director of Translational Research
    Center for Inflammatory Bowel Disease
    Beth Israel Deaconess Medical Center
    Boston, MA

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Medtelligence. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Disclosure of Conflicts of Interest

    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty

    • Dr. Cheifetz: Consulting Fees: Janssen, AbbVie, Takeda, Pfizer, Samsung, Arena, Bacainn; Contracted Research: Miraca
    • Dr. Moss: Consulting Fees: Janssen, Boehringer Ingelheim

    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Medtelligence planners and managers have nothing to disclose.

  • Method of Participation and Request for Credit

    There are no fees for participating and receiving CME credit for this activity. During the period December 3, 2018 through December 3, 2019, participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, complete the post-test and evaluation. Participants who successfully complete the activity, post-test, and evaluation will have a statement of credit made available immediately.

    If you have any questions regarding the CME certification of this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.

  • Disclosure of Unlabeled Use

    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

Facebook Comments

Sign up for the Medtelligence newsletters.
Comprehensive Cardiology Education.

Better education for a better you.

* Required
Optional
Register

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free